European Heart Journal - Cardiovascular Pharmacotherapy最新文献

{"title":"Inhibition of interleukin-1 or -6 after myocardial infarction: pros, cons, and future perspectives.","authors":"Mattia Galli, Filippo Luca Gurgoglione, Sebastiano Sciarretta, Antonio Abbate","doi":"10.1093/ehjcvp/pvaf022","DOIUrl":"10.1093/ehjcvp/pvaf022","url":null,"abstract":"","PeriodicalId":11982,"journal":{"name":"European Heart Journal - Cardiovascular Pharmacotherapy","volume":" ","pages":"321"},"PeriodicalIF":5.3,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12231123/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term antiplatelet monotherapy after PCI: searching for the smart choice.","authors":"Felice Gragnano, Vincenzo De Sio, Mattia Galli, Paolo Calabrò","doi":"10.1093/ehjcvp/pvaf032","DOIUrl":"10.1093/ehjcvp/pvaf032","url":null,"abstract":"","PeriodicalId":11982,"journal":{"name":"European Heart Journal - Cardiovascular Pharmacotherapy","volume":" ","pages":"322"},"PeriodicalIF":5.3,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12231120/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144004433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expert opinion on the integration of combination therapy into the treatment algorithm for the management of dyslipidaemia: the integration of ezetimibe and bempedoic acid may enhance goal attainment.","authors":"Klaus G Parhofer, Carlos Aguiar, Maciej Banach, Heinz Drexel, Ioanna Gouni-Berthold, Leopoldo Pérez de Isla, Ernst Rietzschel, Alberto Zambon, Kausik K Ray","doi":"10.1093/ehjcvp/pvaf007","DOIUrl":"10.1093/ehjcvp/pvaf007","url":null,"abstract":"<p><p>The clinically important link between LDL cholesterol (LDL - C) lowering and cardiovascular (CV) risk reduction is well-established and reflected in the 2019 European Society of Cardiology/European Atherosclerosis Society guidelines for the management of dyslipidaemia. They recommend a stepwise approach to reaching LDL - C goals, beginning with statin monotherapy at the highest tolerated dose. However, real-world data show a large gap between guideline LDL - C goal recommendations and their achievement in clinical practice. The treatment paradigm should shift from the concept of high-intensity statins to that of high-intensity, lipid-lowering therapy (LLT), preferably as upfront combination LLT, to overcome the residual CV risk associated with inadequate lipid management. A multidisciplinary expert panel convened to propose treatment algorithms to support this treatment approach in patients at high and very high CV risk. The experts completed a questionnaire on the benefits of combination therapy and the role that novel LLTs, including bempedoic acid, might play in future guidelines. The integration of new LLTs into the suggested treatment algorithms for patients at high CV risk, very high CV risk, and those with complete or partial statin intolerance was discussed. Each algorithm considers baseline CV risk and LDL - C levels when recommending the initial treatment strategy. This expert consensus endorses the use of statin combination therapy as first-line therapy in patients at high and very high CV risk, and, in some circumstances, in patients with statin intolerance when appropriate. Given recent, compelling evidence, including real-world data, combination therapy as first-line treatment should be considered to help patients achieve their LDL - C goals.</p>","PeriodicalId":11982,"journal":{"name":"European Heart Journal - Cardiovascular Pharmacotherapy","volume":" ","pages":"367-379"},"PeriodicalIF":5.3,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12231129/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143572368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SGLT-2 inhibitors in cancer patients with diabetes: when cardioprotection is key.","authors":"Mattia Brambilla, Bianca Larroux, Aldo Bonaventura","doi":"10.1093/ehjcvp/pvaf038","DOIUrl":"10.1093/ehjcvp/pvaf038","url":null,"abstract":"","PeriodicalId":11982,"journal":{"name":"European Heart Journal - Cardiovascular Pharmacotherapy","volume":" ","pages":"353-355"},"PeriodicalIF":6.1,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12231135/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144119205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early initiation of SGLT2 inhibitors after acute myocardial infarction.","authors":"Andeas Hammer, Samuel Sossalla, Patrick Sulzgruber","doi":"10.1093/ehjcvp/pvaf020","DOIUrl":"10.1093/ehjcvp/pvaf020","url":null,"abstract":"","PeriodicalId":11982,"journal":{"name":"European Heart Journal - Cardiovascular Pharmacotherapy","volume":" ","pages":"365-366"},"PeriodicalIF":5.3,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12231121/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143959839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"We have much more to learn about sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists.","authors":"Stefan Agewall","doi":"10.1093/ehjcvp/pvaf039","DOIUrl":"10.1093/ehjcvp/pvaf039","url":null,"abstract":"","PeriodicalId":11982,"journal":{"name":"European Heart Journal - Cardiovascular Pharmacotherapy","volume":" ","pages":"319-320"},"PeriodicalIF":5.3,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12231122/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144505248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Can sodium-glucose cotransporter-2 inhibitors stabilize coronary atherosclerotic plaques? Evidence from imaging studies.","authors":"Filippo Luca Gurgoglione, Filippo Crea, Giampaolo Niccoli, Mattia Galli","doi":"10.1093/ehjcvp/pvaf025","DOIUrl":"10.1093/ehjcvp/pvaf025","url":null,"abstract":"","PeriodicalId":11982,"journal":{"name":"European Heart Journal - Cardiovascular Pharmacotherapy","volume":" ","pages":"323"},"PeriodicalIF":5.3,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12231125/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143987341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"News in cardiovascular pharmacotherapy from the ACC.25 Meeting.","authors":"Eva Delpón, Ricardo Caballero, Juan Tamargo","doi":"10.1093/ehjcvp/pvaf029","DOIUrl":"10.1093/ehjcvp/pvaf029","url":null,"abstract":"","PeriodicalId":11982,"journal":{"name":"European Heart Journal - Cardiovascular Pharmacotherapy","volume":" ","pages":"393-396"},"PeriodicalIF":5.3,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12231124/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143980473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tolerability and efficacy of sodium-glucose co-transporter 2 inhibitors in patients with cardiac amyloidosis: a meta-analysis of observational studies.","authors":"Renzo Laborante, Stefano Elia, Gianluigi Savarese, Giuseppe Patti, Domenico D'Amario","doi":"10.1093/ehjcvp/pvaf033","DOIUrl":"10.1093/ehjcvp/pvaf033","url":null,"abstract":"<p><strong>Aims: </strong>The role of sodium-glucose co-transporter 2 inhibitors (SGLT2i) in patients with cardiac amyloidosis (CA) is controversial. However, they have shown encouraging results in several clinical settings, including heart failure, myocardial infarction, chronic kidney disease, and various forms of restrictive cardiomyopathy. The current study aims to evaluate the tolerability and efficacy of SGLT2i in patients with CA.</p><p><strong>Methods and results: </strong>PubMed, Scopus, Cochrane Library, and Embase were scanned for eligible articles up to 28th of March 2025. Safety endpoints included the cumulative prevalence of adverse events (AEs) and drug discontinuation (DD) in the SGLT2i-group. Efficacy endpoints were the pooled risk ratio (RR) of all-cause death (ACD) and hospitalization due to worsening heart failure (WHF) between treatment- and control-groups, as well as the difference between mean change of N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels in both treatment- and control-groups. Thirteen observational studies, encompassing 19 227 patients, were included in the meta-analysis. Sodium-glucose co-transporter 2 inhibitors use in patients with CA resulted to be tolerable, as demonstrated by a low absolute cumulative prevalence of both AEs [8%; 95% confidence interval (CI) 2-17, nine studies, 603 patients] and DD (4%; 95% CI: 1-7, nine studies, 603 patients). Furthermore, its use was associated with a reduction in the risk of ACD (RR 0.59; 95% CI: 0.48-0.72) and NT-proBNP levels (median difference: -525.54; 95% CI: -718.09 to -332.98), despite no significant association with WHF was noted.</p><p><strong>Conclusion: </strong>The administration of SGLT2i proved to be well tolerated in patients with CA. Randomized controlled trials are urgently needed to confirm the prognostic improvement associated with their use in this clinical setting.</p><p><strong>Study registration: </strong>CRD42025632733.</p>","PeriodicalId":11982,"journal":{"name":"European Heart Journal - Cardiovascular Pharmacotherapy","volume":" ","pages":"356-364"},"PeriodicalIF":5.3,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12231128/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144086096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nonsteroidal Mineralocorticoid Receptor Antagonists and Cardiovascular Events in Type 2 Diabetes: A Retrospective Study.","authors":"Yi-Hsien Chen, Yu-Wei Fang, Mon-Ting Chen, Hung-Hsiang Liou, Ming-Hsien Tsai","doi":"10.1093/ehjcvp/pvaf048","DOIUrl":"https://doi.org/10.1093/ehjcvp/pvaf048","url":null,"abstract":"<p><strong>Aims: </strong>Nonsteroidal mineralocorticoid receptor antagonists such as finerenone mitigate cardiorenal risks in patients with type 2 diabetes mellitus (T2DM). Real-world evidence comparing finerenone with spironolactone and eplerenone remains limited. This study aimed to evaluate the cardiovascular outcomes in T2DM patients treated with finerenone versus spironolactone or eplerenone using real-world data.</p><p><strong>Methods and results: </strong>A retrospective cohort analysis was conducted using the TriNetX US Collaborative Network database. Adult patients with T2DM who were newly prescribed finerenone, spironolactone, or eplerenone were included (2021-2024). One-to-one propensity score matching was applied to eligible participants, resulting in 2,957 finerenone users matching with spironolactone users and 1,603 finerenone users matching with eplerenone users. Cardiovascular outcomes, including major adverse cardiovascular events (MACE), heart failure, and mortality, were assessed over 24 months of follow-up. Hazard ratios (HR) with 95% confidence intervals (CI) were calculated using Cox regression models. Finerenone users had significantly lower rates of MACE compared with spironolactone users (HR: 0.53, 95% CI: 0.43-0.66) and eplerenone (HR: 0.66, 95% CI: 0.50-0.87). Mortality was also reduced with finerenone versus spironolactone (HR: 0.45, 95% CI: 0.35-0.57) and eplerenone (HR: 0.56, 95% CI: 0.41-0.75). Heart failure events were fewer with finerenone than with spironolactone (HR: 0.70, 95% CI: 0.55-0.90) and eplerenone (HR: 0.70, 95% CI: 0.50-0.99). Differences in acute myocardial infarction and stroke rates were not statistically significant.</p><p><strong>Conclusions: </strong>Finerenone demonstrated superior cardiovascular outcomes compared with spironolactone and eplerenone in patients with T2DM with significant reductions in MACE, mortality, and heart failure events.</p>","PeriodicalId":11982,"journal":{"name":"European Heart Journal - Cardiovascular Pharmacotherapy","volume":" ","pages":""},"PeriodicalIF":5.3,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144274525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}